Biotronik Prepares For Next Era Of Drug-Eluting Stents
Executive Summary
Biotronik is touting successful clinical trial results with its Orsiro sirolimus-eluting coronary stent while continuing to develop a resorbable stent.
You may also be interested in...
Cardiovascular Catch-Up: TAVR Withstands Delta Virus So Far; Stereotaxis Robot Succeeds In Trial
The impact of the Delta variant of COVID-19 on procedure volumes remains a major concern for transcatheter valve makers, Abbott launches a new PFO closure device, and more highlights from the cardiovascular technology market in early October.
Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication
The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.
Start-Up Spotlight: Elixir Works To 'Uncage' The Coronary After Intervention
The company is sponsoring INFINITY SWEDEHEART, a randomized trial of its DynamX Bioadaptor, a unique metallic coronary artery implant that adapts to vessel physiology.